Home・Akciju saraksts・Moderna Inc

Moderna Inc

Atvērts

SektorsVeselības aprūpe

138.5 -4.46

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

130

Max

144.88

Galvenie mērījumi
By Trading Economics
Ienākumi	561M -782M
Pārdošana	-244M 145M
EPS	-1.97
Peļņas marža	-539.31
Darbinieki	4,700
EBITDA	554M -704M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	-37.04% downside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 5. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	3.7B 26B
Iepriekšējā atvēršanas cena	142.96
Iepriekšējā slēgšanas cena	138.5

Ziņu noskaņojums

By Acuity

50%

147 / 340 Rangs Healthcare

Moderna Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 21. aug. 23:36 UTC

Social Media

Moderna Inc. shares are higher in after-market trading following a successful melanoma trial, reflecting strong investor interest and elevated trading volume.

2026. g. 20. aug. 23:01 UTC

Social Media

Moderna Inc. shares are lower in after-market trading amid skepticism about its mRNA cancer vaccine and broader declines in U.S. stocks following Walmart's poor performance.

2026. g. 19. aug. 23:51 UTC

Event

Social Media

Moderna shares lower in after-market trading despite positive Phase 3 results for its mRNA cancer vaccine, which boosted market cap by over $50 billion.

2026. g. 18. aug. 23:51 UTC

Social Media

MAHA shares are lower in after-market trading amid growing disappointment over the FDA's approval of Moderna's mRNA flu shot and recent departures from the agency.

2026. g. 17. aug. 20:06 UTC

Social Media

Concerns about the FDA's approval of Moderna's flu vaccine persist. Shares are higher today, remaining above the 20-day moving average.

2026. g. 14. aug. 23:51 UTC

Social Media

Moderna shares are lower in after-market hours amid concerns over the FDA's approval of its mRNA flu vaccine and modest trial data effectiveness.

2026. g. 13. aug. 23:21 UTC

Social Media

Moderna's first mRNA flu shot receives FDA approval, despite concerns over a high adverse reaction rate. Shares are higher in after-market trading.

2026. g. 12. aug. 23:51 UTC

Moderna Inc shares are lower in after-market hours with no specific news identified. Recent easing inflation has influenced broader market sentiment.

2026. g. 10. aug. 19:36 UTC

Social Media

The FDA has approved Moderna's mRNA flu vaccine for adults 50 and older. Shares are advancing modestly amid concerns over safety and efficacy.

2026. g. 7. aug. 19:52 UTC

Social Media

The FDA approved Moderna's mRNA flu vaccine, mFlusiva, for adults 50 and older. Shares are higher during Friday's trading session.

2026. g. 6. aug. 23:06 UTC

Social Media

Moderna's mRNA flu vaccine, "mFlusiva," receives FDA approval for adults aged 50 to 64, boosting shares higher in after-market trading.

2026. g. 5. aug. 19:46 UTC

Social Media

Event

Moderna Inc. shares are lower as disappointing ADP employment data weighs on market sentiment. The FDA has set a decision date for its mFlusiva vaccine.

2026. g. 4. aug. 20:07 UTC

Social Media

News

Moderna initiates Phase 1 trial for mRNA-1469 vaccine, backed by CEPI's $50 million funding. Shares are higher despite earlier session pullback.

2026. g. 3. aug. 20:03 UTC

News

Moderna Inc. shares are advancing as Citigroup raises its price target to $60 amid broader market strength and gains in major tech stocks.

2026. g. 31. jūl. 23:26 UTC

Moderna Inc. shares are lower in after-hours trading, continuing a decline from Friday's close without any specific news to explain the movement.

2026. g. 30. jūl. 23:51 UTC

Moderna Inc shares are higher in after-market trading, driven by a significant advance in the overall market, despite earlier fluctuations during the session.

2026. g. 29. jūl. 23:51 UTC

Moderna Inc is rising in after-market trading, aligning with broader market gains. The stock showed volatility earlier in the session without specific news driving the move.

2026. g. 28. jūl. 18:36 UTC

Moderna Inc shares are lower today, continuing a decline from Monday's close amid risk-off sentiment following significant declines in Asian markets.

2026. g. 27. jūl. 19:07 UTC

Social Media

Moderna Inc. is advancing as it initiates a Phase 1 trial for its mRNA-4200 cancer vaccine, with the first U.S. participant dosed on July 16, 2026.

2026. g. 24. jūl. 19:03 UTC

Social Media

News

Moderna Inc shares are lower today amid mixed options sentiment and increased demand for downside protection ahead of its upcoming earnings report.

2026. g. 23. jūl. 19:56 UTC

Social Media

News

Moderna Inc shares are lower, trading around $57.25, as options activity remains light. An mRNA vaccine is set for a Phase 1 trial in August.

2026. g. 21. jūl. 20:07 UTC

News

Social Media

Goldman Sachs raised Moderna's price target to $49.00 while maintaining a Neutral rating, reflecting a more favorable outlook on the company's valuation. Shares are higher today.

2026. g. 20. jūl. 23:46 UTC

Moderna Inc shares are lower in after-market hours amid rising Treasury yields and broader market trends, with no specific company news identified.

Salīdzinājums

Cenas izmaiņa

Moderna Inc Prognoze

Cenas mērķis

By TipRanks

-37.04% uz leju

Prognoze 12 mēnešiem

Vidējais 91.38 USD -37.04%

Augstākais 170 USD

Zemākais 40 USD

Pamatojoties uz 15 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Moderna Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

15 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 15 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Moderna Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

147 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Moderna Inc

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.